Article Text

Download PDFPDF
Original research article
Epidemiological changes in Eisenmenger syndrome in the Nordic region in 1977–2012

Footnotes

  • Contributors CSH, ASJ and LS designed the study and are responsible for the overall content. CSH, KS, EN, BJ, TK, MD, ME, HH, MT and UT collected the data. CSH analysed data and wrote the manuscript. ASJ, KS, EN, BJ, TK, MD, ME, HH, MT, UT and LS critically reviewed the manuscript and provided scientific input.

  • Funding This study was financed by an educational grant from Actelion Denmark, a branch of Actelion Pharmaceuticals in Sweden.

  • Disclaimer Actelion Pharmaceuticals was not involved in the writing or editing of the report or analysis of the data.

  • Competing interests CSH received an educational grant from Actelion Pharmaceuticals. ASJ received a research grant and speaker’s fees from Actelion Pharmaceuticals. BJ received a speaker fee from Actelion Pharmaceuticals. UT received fees for lectures and being a member of advisory board from Actelion Pharmaceuticals. LS received research grant, as well as fee for lectures and being a member of advisory board from Actelion Pharmaceuticals.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors CSH, ASJ and LS designed the study and are responsible for the overall content. CSH, KS, EN, BJ, TK, MD, ME, HH, MT and UT collected the data. CSH analysed data and wrote the manuscript. ASJ, KS, EN, BJ, TK, MD, ME, HH, MT, UT and LS critically reviewed the manuscript and provided scientific input.

  • Funding This study was financed by an educational grant from Actelion Denmark, a branch of Actelion Pharmaceuticals in Sweden.

  • Disclaimer Actelion Pharmaceuticals was not involved in the writing or editing of the report or analysis of the data.

  • Competing interests CSH received an educational grant from Actelion Pharmaceuticals. ASJ received a research grant and speaker’s fees from Actelion Pharmaceuticals. BJ received a speaker fee from Actelion Pharmaceuticals. UT received fees for lectures and being a member of advisory board from Actelion Pharmaceuticals. LS received research grant, as well as fee for lectures and being a member of advisory board from Actelion Pharmaceuticals.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles